Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | EBP | Q15125 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CEL | P19835 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412738 | 1.00 | SIGMAR1 (0.56) | SIGMAR1TMEM97EBPTSHRCYP2D6 | |
| Hydrochloric Acid SCHEMBL9148670 | 0.99 | SIGMAR1 (0.55) | SIGMAR1TMEM97EBPTSHRCYP2D6 | |
| SCHEMBL26765552 | 0.85 | SIGMAR1 (0.44) | SIGMAR1TMEM97EBPSLC6A4NOS3 | |
| SCHEMBL26765546 | 0.85 | SIGMAR1 (0.43) | SIGMAR1TMEM97EBPTSHRCYP2D6 | |
| SCHEMBL7135842 | 0.85 | SIGMAR1 (0.41) | SIGMAR1TMEM97EBPTSHRCYP2D6 | |
| SCHEMBL7144481 | 0.84 | SIGMAR1 (0.38) | SIGMAR1TMEM97EBPTSHRCYP2D6 | |
| Hydrochloric Acid SCHEMBL9151770 | 0.84 | SIGMAR1 (0.43) | SIGMAR1TMEM97EBPSLC6A4NOS3 | |
| SCHEMBL8329033 | 0.84 | SIGMAR1 (0.42) | SIGMAR1TMEM97EBPTSHRCYP2D6 | |
| Hydrochloric Acid SCHEMBL9319142 | 0.84 | SIGMAR1 (0.42) | SIGMAR1TMEM97EBPTSHRCYP2D6 | |
| Hydrochloric Acid SCHEMBL7310901 | 0.83 | SIGMAR1 (0.41) | SIGMAR1TMEM97EBPTSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0917464-A1 | USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION | SANOFI (FR) | 1999-05-26 | — | — | EP | claimed |
| WO-1998004251-A1 | USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION | SANOFI (FR) | 1998-02-05 | — | — | WO | claimed |
| US-20260062374-A1 | PROCESS FOR THE PREPARATION OF A BENZENE DERIVATIVE | MELETIOS THERAPEUTICS (FR) | 2026-03-05 | — | — | US | disclosed |
| WO-2024042246-A1 | PROCESS FOR THE PREPARATION OF A BENZENE DERIVATIVE | MELETIOS THERAPEUTICS (FR) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042246-A1 | PROCESS FOR THE PREPARATION OF A BENZENE DERIVATIVE | MELETIOS THERAPEUTICS (FR) | 2024-02-29 | — | — | WO | disclosed |
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | MELETIOS THERAPEUTICS (FR) | 2023-11-16 | — | — | US | disclosed |
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | MELETIOS THERAPEUTICS (FR) | 2023-11-16 | — | — | US | disclosed |
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | MELETIOS THERAPEUTICS (FR) | 2023-11-16 | — | — | US | disclosed |
| CN-1154483-C | Use of amines to produce drugs for preventing tumour cell proliferation | ��ŵ��-ʥ�������ɷ�����˾ | 2004-06-23 | — | — | CN | disclosed |
| US-6235791-B1 | USING CIS N-CYCLOHEXYL-N-ETHYL(3-(3-CHLORO-CYCLOHEXYLPHENYL)ALLYL)AMINE | SANOFI-SYNTHELABO (FR) | 2001-05-22 | — | — | US | disclosed |
| CN-1226825-A | Use of amines to produce drugs for preventing tumour cell proliferation | SANOFI SA (FR) | 1999-08-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062374-A1 | PROCESS FOR THE PREPARATION OF A BENZENE DERIVATIVE | BRDT, CYP3A7, TP53 | SIGMAR1 39/4885TMEM97 7/4885EBP 249/4885 |
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | ACE, HAVCR2, FURIN | SIGMAR1 3429/4885TMEM97 3055/4885EBP 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.